CSIMarket Company Name, Ticker, Suppliers, else..
 
Tc Biopharm holdings Plc  (TCBP)
Other Ticker:  
 
 
Price: $0.3810 $-0.01 -1.804%
Day's High: $0.42 Week Perf: -23.8 %
Day's Low: $ 0.36 30 Day Perf: -11.4 %
Volume (M): 1,272 52 Wk High: $ 9.61
Volume (M$): $ 485 52 Wk Avg: $1.87
Open: $0.36 52 Wk Low: $0.33



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Tc Biopharm Holdings Plc


   Company Address: Maxim 1, 2 Parklands Way Motherwell 0
   Company Phone Number: 433 7557   Stock Exchange / Ticker: NASDAQ TCBP
   TCBP is expected to report next financial results on April 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Lineage Cell Therapeutics Inc

A loss of $-0.04 per Share at the Lineage Cell Therapeutics Inc amid the fiscal time-frame ending September 30 2023

For the fiscal time-frame ending September 30 2023 LCTX lost money of $-0.04 per share compare to $-0.04 a year before and surged loss from $-0.03 per share from the previous quarter. The revenue fell sharply by -58.439 % to $1.25 million from $3.00 million in the comparable quarter a year before and sequentially Revenue Tumbled by -61.364 % from $3.23 million.

Bio Techne Corp

Reduction in Earnings while revenue grew in the July to September 30 2023 fiscal time-frame

Revenue improvement of 2.447 %, could not prevent income decline of -85.97 % in the most recent fiscal period, relative to comparable reporting period a year before. revenue were at $276.19 million and eps at $0.31.

Anavex Life Sciences Corp

Anavex Life Sciences Corp's EPS Soars by 454.76% Despite Decline in Revenue during Q4 2023


Date: November 30, 2023
Anavex Life Sciences Corp, a renowned Biotechnology and Pharmaceuticals company, recently reported its financial results for the fiscal fourth quarter of 2023. Despite a sharp decline in revenue, the company's earnings per share (EPS) witnessed a commendable surge. Let's delve into the details of these results and analyze what this means for the future of the company.
In the fiscal fourth quarter of 2023, Anavex Life Sciences Corp reported a staggering EPS growth of 454.76%. The EPS rose to $0.48 per share, compared to $0.09 per share in the same quarter a year ago. Moreover, the company was able to turn its EPS positive, bouncing back from a loss of $-0.14 per share in the prior quarter. This robust growth in earnings is undoubtedly a positive sign for shareholders and investors.
Twist Bioscience Corporation

Twist Bioscience Corporation Successfully Narrows Deficit, Demonstrating Promising Financial Recovery from July to September 2023

Twist Bioscience Corporation, a leading biotechnology and pharmaceutical company, has showcased strong financial performance in the third quarter of 2023. The company reported a decrease in loss per share, improved income per share, and a significant increase in revenue.
Compared to the previous year, Twist Bioscience Corporation reduced its loss per share from $0.81 to $0.80. Additionally, income per share improved from $1.01 to $0.80 from the previous quarter. These positive results indicate the company's efforts to minimize losses and improve profitability.
Agentix Corp

Article Title: FWDR Announces Second Quarter 2024 Performance, Exhibiting Growth Potential in Biotechnology and Pharmaceuticals Sector



In the fast-paced world of Biotechnology and Pharmaceuticals, where industry leaders often dominate the headlines, it is crucial to keep an eye on lesser-known businesses that may harbor potential for growth and success. One such company, FWDR, recently announced its financial results for the second quarter of 2024, providing some encouraging news and offering investors assurance about its future prospects.
Operating Shortfall Improvement:
FWDR disclosed an operating shortfall of $-0.353155 million for Q2 2024. Although it cannot be considered a significant financial achievement on its own, the fact that it represents an improvement compared to the same period in the previous year is noteworthy. In Q2 2023, FWDR had reported a larger operating shortfall of $-0.42433 million. This improvement indicates the company's commitment to enhancing its financial performance and marks a step in the right direction.





 

Tc Biopharm Holdings Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com